Share-based Payment Arrangement, Expense of Kymera Therapeutics, Inc. from 30 Sep 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Kymera Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2019 to 31 Dec 2025.
  • Kymera Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $14,453,000, a 4.7% increase year-over-year.
  • Kymera Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $59,904,000, a 8.9% increase year-over-year.
  • Kymera Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2025 was $59,904,000, a 8.9% increase from 2024.
  • Kymera Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $55,012,000, a 28% increase from 2023.
  • Kymera Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $43,118,000, a 22% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Kymera Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $59,904,000 $14,453,000 +$654,000 +4.7% 01 Oct 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q3 2025 $59,250,000 $15,802,000 +$898,000 +6% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $58,352,000 $15,415,000 +$1,074,000 +7.5% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $57,278,000 $14,234,000 +$2,266,000 +19% 01 Jan 2025 31 Mar 2025 10-Q 09 May 2025 2025 Q1
Q4 2024 $55,012,000 $13,799,000 +$2,902,000 +27% 01 Oct 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q3 2024 $52,110,000 $14,904,000 +$3,249,000 +28% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $48,861,000 $14,341,000 +$3,160,000 +28% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $45,701,000 $11,968,000 +$2,583,000 +28% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2025 2025 Q1
Q4 2023 $43,118,000 $10,897,000 +$1,988,000 +22% 01 Oct 2023 31 Dec 2023 10-K 26 Feb 2026 2025 FY
Q3 2023 $41,130,000 $11,655,000 +$2,579,000 +28% 01 Jul 2023 30 Sep 2023 10-Q 31 Oct 2024 2024 Q3
Q2 2023 $38,551,000 $11,181,000 +$1,559,000 +16% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $36,992,000 $9,385,000 +$1,512,000 +19% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $35,480,000 $8,909,000 +$231,000 +2.7% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $35,249,000 $9,076,000 +$1,680,000 +23% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $33,569,000 $9,622,000 +$3,896,000 +68% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $29,673,000 $7,873,000 +$4,701,000 +148% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $24,972,000 $8,678,000 +$6,851,000 +375% 01 Oct 2021 31 Dec 2021 10-K 22 Feb 2024 2023 FY
Q3 2021 $18,121,000 $7,396,000 +$5,068,000 +218% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $13,053,000 $5,726,000 +$5,062,000 +762% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $7,991,000 $3,172,000 +$2,801,000 +755% 01 Jan 2021 31 Mar 2021 10-Q 03 May 2022 2022 Q1
Q4 2020 $5,190,000 $1,827,000 01 Oct 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
Q3 2020 $2,328,000 +$2,094,000 +895% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $664,000 01 Apr 2020 30 Jun 2020 10-Q 06 Aug 2021 2021 Q2
Q1 2020 $371,000 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q3 2019 $234,000 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3

Kymera Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $59,904,000 +$4,892,000 +8.9% 01 Jan 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
2024 $55,012,000 +$11,894,000 +28% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
2023 $43,118,000 +$7,638,000 +22% 01 Jan 2023 31 Dec 2023 10-K 26 Feb 2026 2025 FY
2022 $35,480,000 +$10,508,000 +42% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $24,972,000 +$19,782,000 +381% 01 Jan 2021 31 Dec 2021 10-K 22 Feb 2024 2023 FY
2020 $5,190,000 +$3,994,000 +334% 01 Jan 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
2019 $1,196,000 01 Jan 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.